Cerity Partners
ARQT icon

Cerity Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Cerity Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Sell
14,756
-9,170
-38% -$214K ﹤0.01% 2605
2026
Q1 		$564K Sell
23,926
-952
-4% -$24.3K ﹤0.01% 2213
2025
Q4 		$722K Buy
24,878
+1,700
+7% +$43.5K ﹤0.01% 1871
2025
Q3 		$437K Buy
23,178
+4,518
+24% +$71.3K ﹤0.01% 2058
2025
Q2 		$262K Sell
18,660
-694
-4% -$9.73K ﹤0.01% 2225
2025
Q1 		$303K Buy
+19,354
New +$273K ﹤0.01% 2009
2024
Q4 		– Sell
-21,102
Closed -$196K – 2429
2024
Q3 		$196K Buy
+21,102
New +$208K ﹤0.01% 2324

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's ARQT Position: Q2 2026 in Review

Cerity Partners reduced its Arcutis Biotherapeutics (ARQT) stake by 38% in Q2 2026, selling an estimated $214K and leaving 14,756 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Cerity Partners first reported a position in ARQT in Q3 2024 and has held it in 7 quarters since. The position peaked at $722K in Q4 2025. 249 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Cerity Partners held 14,756 shares of Arcutis Biotherapeutics worth $387K as of Q2 2026.
  • Cerity Partners sold 9,170 Arcutis Biotherapeutics shares in Q2 2026, an estimated $214K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2605 holding.
  • Cerity Partners first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cerity Partners's Arcutis Biotherapeutics position peaked at $722K in Q4 2025.
  • 249 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.